To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets
NCT ID: NCT00913419
Last Updated: 2017-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
1988-11-30
1988-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic Study of MIN-101 in Healthy Subjects
NCT02232529
Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males
NCT00814931
Cost-effectiveness of CYP2D6 and CYP2C19 Genotyping in Psychiatric Patients in Curacao
NCT02713672
Alleviating the Metabolic Side Effects of Antipsychotic Medications
NCT01567124
To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions
NCT00913952
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories
Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories
2
Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp \& Dohme
Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories
Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Treatment for drug or alcohol dependence.
19 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sandoz
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sandoz Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
A. Orson Brod, M.D.
Role: PRINCIPAL_INVESTIGATOR
PharmaKineticsLaboratories, Inc
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9038A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.